https://www.wsj.com/articles/why-stanfords-leaders-tolerate-anti-semitism-free-speech-academia-professors-249819a5?mod=opinion_lead_pos6
After Hamas massacred some 1,400 Israelis on Oct. 7, many Stanford students marched in support of the terrorist group, chanting “2, 4, 6, 8, smash the Zionist settler state.” University leaders responded with a statement supporting “academic freedom,” including the “expression of controversial and even offensive views.”
This is the same university where administrators last year undertook an Elimination of Harmful Language Initiative, which published a catalog of words and phrases to be removed from the school’s websites. Among the proscribed terms: “American,” “immigrant” and “blind study.”
Stanford’s motto is “let the winds of freedom blow,” but many administrators and faculty want it to blow only from the left. Denouncing anti-Semitic protests wouldn’t chill academic freedom on campus; it would serve as a desperately needed show of moral clarity amid a tempest of false equivalence.
But cowardly university leaders are afraid of provoking leftist professors and staff. Recall what happened to Stanford’s previous president. Marc Tessier-Lavigne, a neuroscientist, announced his resignation in July following a series of reports in the student newspaper, the Stanford Daily, that accused him of research fraud. Much of the reporting turned out to be inaccurate, but that didn’t matter. The die had already been cast against him.
On Nov. 29, 2022, freshman Theo Baker—whose parents, Susan Glasser and Peter Baker, are journalists at the New Yorker and the New York Times—reported that images in some of Mr. Tessier-Lavigne’s papers on Alzheimer’s disease appeared to have been manipulated and that his research was under “investigation for scientific misconduct” by the European Molecular Biology Organization Journal.
Mr. Baker subsequently wrote several stories based on anonymous sources who alleged that Mr. Tessier-Lavigne had tried to conceal fraud in his studies. Mr. Baker focused particularly on a 2009 Alzheimer’s study in the journal Nature that Mr. Tessier-Lavigne led while employed by the drugmaker Genentech.